0001193125-25-264708
SEC filingRevenue fell 44% YoY to $14.5M in Q3 2025, driven by enterprise and population sequencing declines, while clinical diagnostics grew 42%.
In Q3 2025, total revenue declined 44% year-over-year to $14.5 million, primarily due to a $4.6 million drop in enterprise sales (Natera) and a $4.2 million decrease in population sequencing (VA MVP), along with a $2.5 million reduction in pharma tests and other revenue. Cost of revenue decreased 26% to $12.6 million, but gross margin contracted sharply from 34.0% in Q3 2024 to 13.2% in Q3 2025, driven by lower fixed overhead absorption and higher clinical diagnostic costs that exceeded reimbursement rates. Operating expenses increased, with R&D up 4% to $12.2 million (higher collaboration costs) and SG&A up 14% to $13.0 million (expanded marketing for NeXT Personal Dx). Net loss improved to $21.7 million (vs. $39.1 million a year ago) due to the absence of a noncash loss on Tempus Warrants, though operating loss widened to $23.3 million from $14.4 million. EPS was -$0.24, compared to -$0.64 in the prior year.
Pharma tests and services (59% of Q3 2025 revenue) fell 16% to $13.1 million, driven by lower Moderna volumes and pricing. Enterprise sales (4%) plunged 88% to $0.7 million as Natera’s minimum volume commitments ended in Q2 2025. Population sequencing (2%) dropped 95% to $0.2 million, reflecting the completion of the prior task order. Clinical diagnostic (3%) rose 42% to $0.4 million on increased NeXT Dx and NeXT Personal Dx private payor reimbursements, and delivered 4,388 clinical tests (up 364% YoY). Other revenue more than doubled to $0.1 million.
Management expects near-term variability in pharma revenue due to trial timing. Enterprise sales are not expected to sustain a long-term Natera relationship. The new VA MVP task order (up to $13.5 million) starting September 30, 2025, provides a base for population sequencing. Clinical diagnostic growth is anticipated to accelerate with Medicare coverage submissions (three pending) and the expanded Tempus partnership (through Nov 2029). Capital expenditures are planned at ~$7 million in 2025 and $13-14 million annually in 2026-2027 to expand NeXT Personal Dx capacity. The company believes current cash ($150.5 million) funds operations for at least 12 months, though additional financing may be sought if needed.
As of September 30, 2025, Personalis held $49.97M in cash and cash equivalents and $100.54M in short-term investments, totaling $150.52M in liquid assets. This compares to $91.42M and $93.59M respectively at December 31, 2024, reflecting a net decrease in cash and equivalents of $41.44M during the nine-month period. Total assets were $242.84M, down from $270.27M at year-end 2024. Stockholders' equity decreased to $171.42M from $202.96M, driven by a net loss of $57.46M partially offset by $17.78M in ATM proceeds and $7.13M in stock-based compensation. Total debt (loans) stood at $2.32M, consisting of $2.45M principal less $0.14M unamortized discount, with $1.47M classified as current. Inventory and other deferred costs were $4.66M, down from $5.94M.
The company has significant operating lease commitments totaling $64.26M in future minimum lease payments, with a present value of $39.56M after imputed interest of $24.71M. The weighted-average remaining lease term is 9.5 years at a discount rate of 10.6%. Lease payments due within one year are $7.23M, with $12.40M due in 1-3 years and $42.80M due beyond 3 years. Additionally, the company has a finance lease for lab equipment with $3.15M in right-of-use assets and $3.15M in liabilities as of September 30, 2025. Contract liabilities (deferred revenue) were $1.46M, down from $3.10M at year-end 2024.
No share repurchases or dividends were reported. Capital expenditures totaled $4.43M for the nine months ended September 30, 2025, representing 8.5% of revenue. Debt activity included $2.59M in new loans (primarily a $2.8M software license financing agreement in January 2025) and $1.72M in repayments, resulting in a net debt increase of $0.54M. The company also raised $17.78M net from ATM equity sales during the period.
The company operates as a single reportable segment: advanced cancer genomic tests and services. Revenue is disaggregated by customer type: Pharma tests and services ($37.75M, 72% of total), Enterprise sales ($5.43M, 10%), Population sequencing ($7.76M, 15%), Clinical diagnostic ($1.16M, 2%), and Other ($0.20M, <1%) for the nine months ended September 30, 2025. Geographically, 90% of revenue came from the United States and 10% from other regions. Key customers include ModernaTX (25% of revenue), VA MVP (15%), and Natera (10%).
Net loss improved slightly to -$57.5M from -$64.9M, but operating cash flow worsened to -$52.7M from -$37.4M, driven by a large working capital outflow in accounts receivable (-$6.2M vs +$4.3M prior) and lower accruals. Noncash adjustments were consistent, with stock-based compensation of $7.1M and depreciation/amortization of $7.6M. Capex increased sharply to $4.4M (from $0.4M), indicating higher investment in property and equipment. FCF (not provided but implied as -$57.1M) remains deeply negative, with no capital returns (no dividends or buybacks). Financing activities provided $19.4M, mainly from ATM equity sales ($17.8M) and loan proceeds ($2.6M), partially offset by loan repayments. The company continues to rely on external funding to cover cash burn. Anomalies include a $2.7M related-party liability change embedded in accounts payable and a $0.1M related-party receivable adjustment.